Literature DB >> 15111263

Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

G A Ricaurte1, U D McCann.   

Abstract

A number of drugs that fall into the broad category of "ring-substituted amphetamines" have been found to be neurotoxic toward brain monoamine neurons in animals. Several of these drugs, including 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and methamphetamine ("speed") and fenfluramine ("Pondimin") have been used or abused by humans. A growing body of evidence indicates that humans, like animals, are susceptible to substituted amphetamine-induced neurotoxic injury, and that consequences of this injury can be subtle. This article will review the effects of ring-substituted amphetamine analogs on brain monoamine neurons, using MDMA as the prototype. Studies documenting MDMA neurotoxic potential toward brain serotonin (5-HT) neurons in animals are summarized first. Human MDMA studies are then discussed, beginning with a consideration of methodological challenges in evaluating the status of 5-HT neurons in the living human brain. Recent findings indicating possible functional alterations in brain serotonergic systems in humans with a history of extensive MDMA exposure are then presented, including some new findings on sleep and personality in abstinent MDMA users.

Entities:  

Year:  2001        PMID: 15111263     DOI: 10.1007/bf03033232

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  95 in total

1.  Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.

Authors:  C J Schmidt; L Wu; W Lovenberg
Journal:  Eur J Pharmacol       Date:  1986-05-13       Impact factor: 4.432

2.  In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain.

Authors:  U Scheffel; Z Szabo; W B Mathews; P A Finley; R F Dannals; H T Ravert; K Szabo; J Yuan; G A Ricaurte
Journal:  Synapse       Date:  1998-06       Impact factor: 2.562

3.  Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness.

Authors:  R M Post; J Kotin; F K Goodwin; E K Gordon
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

4.  Relationship of monoamine metabolites in human cerebrospinal fluid to age.

Authors:  M B Bowers; F A Gerbode
Journal:  Nature       Date:  1968-09-21       Impact factor: 49.962

5.  Axonal transport in serotonin neurons of the midbrain raphe.

Authors:  A E Halaris; B E Jones; R Y Moore
Journal:  Brain Res       Date:  1976-05-14       Impact factor: 3.252

6.  The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

Authors:  T Vander Borght; M Kilbourn; T Desmond; D Kuhl; K Frey
Journal:  Eur J Pharmacol       Date:  1995-12-29       Impact factor: 4.432

7.  Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

Authors:  U D McCann; Z Szabo; U Scheffel; R F Dannals; G A Ricaurte
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

8.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

Review 9.  Central serotonin and impulsive aggression.

Authors:  E F Coccaro
Journal:  Br J Psychiatry Suppl       Date:  1989-12

10.  Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine.

Authors:  M A Wilson; G A Ricaurte; M E Molliver
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

View more
  6 in total

1.  Neurotoxicity and substance abuse: further fuel for regulatory dilemma.

Authors:  T Archer; T Palomo; R M Kostrzewa
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

2.  Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Authors:  Stephen J Kish; Jason Lerch; Yoshiaki Furukawa; Junchao Tong; Tina McCluskey; Diana Wilkins; Sylvain Houle; Jeffrey Meyer; Emanuela Mundo; Alan A Wilson; Pablo M Rusjan; Jean A Saint-Cyr; Mark Guttman; D Louis Collins; Colin Shapiro; Jerry J Warsh; Isabelle Boileau
Journal:  Brain       Date:  2010-05-17       Impact factor: 13.501

3.  MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain.

Authors:  Shane A Perrine; Farhad Ghoddoussi; Mark S Michaels; Elisabeth M Hyde; Donald M Kuhn; Matthew P Galloway
Journal:  Neurotoxicology       Date:  2010-08-26       Impact factor: 4.294

4.  Altered visual perception in long-term ecstasy (MDMA) users.

Authors:  Claire White; John Brown; Mark Edwards
Journal:  Psychopharmacology (Berl)       Date:  2013-04-23       Impact factor: 4.530

5.  Brain serotonin transporter in human methamphetamine users.

Authors:  Stephen J Kish; Paul S Fitzmaurice; Isabelle Boileau; Gregory A Schmunk; Lee-Cyn Ang; Yoshiaki Furukawa; Li-Jan Chang; Dennis J Wickham; Allan Sherwin; Junchao Tong
Journal:  Psychopharmacology (Berl)       Date:  2008-10-08       Impact factor: 4.530

6.  Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use.

Authors:  Eugene A Kiyatkin; Albert H Kim; Ken T Wakabayashi; Michael H Baumann; Yavin Shaham
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.